| 1. |
中華醫學會呼吸病學分會慢性阻塞性肺疾病學組, 中國醫師協會呼吸醫師分會慢性阻塞性肺疾病工作委員會. 慢性阻塞性肺疾病診治指南(2021年修訂版)[J]. 中華結核和呼吸雜志, 2021, 44(3): 170-205.
|
| 2. |
陳典, 隆寰宇, 張叢溪, 等. 2025年GOLD慢性阻塞性肺疾病診斷、治療、管理及預防全球策略更新要點解讀[J]. 中國全科醫學, 2025, 28(16): 1937-1949.
|
| 3. |
Yang T, Cai B, Cao B, et al. Exacerbation in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)[J]. Ther Adv Respir Dis, 2023, 17: 17534666231167353.
|
| 4. |
中華醫學會呼吸病學分會, 中華預防醫學會呼吸病預防與控制專業委員會, 中國醫師協會呼吸醫師分會, 等. 慢性阻塞性肺疾病急性加重圍出院期管理與隨訪指南(2024年版)[J]. 中華結核和呼吸雜志, 2024, 47(11): 1048-1068.
|
| 5. |
Ioannides AE, Whittaker HR, Quint JK. Major adverse cardiovascular events and cause-specific mortality after hospitalisation in COPD[J]. Int J Chron Obstruct Pulmon Dis, 2025, 20: 2549-2560.
|
| 6. |
Hurst JR, Gale CP. MACE in COPD: addressing cardiopulmonary risk[J]. Lancet Respir Med, 2024, 12(5): 345-348.
|
| 7. |
Kallis C, Kaura A, Samuel NA, et al. The relationship between cardiac troponin in people hospitalised for exacerbation of copd and major adverse cardiac events (MACE) and COPD readmissions[J]. Int J Chron Obstruct Pulmon Dis, 2023, 18: 2405-2416.
|
| 8. |
王亞芬, 曠湘楠, 尹玉潔, 等. 慢性阻塞性肺疾病合并心血管疾病的研究進展[J]. 醫學研究生學報, 2022, 35(4): 418-423.
|
| 9. |
賈睿奕, 張勃, 于國云, 等. 慢性阻塞性肺疾病合并高血壓對心血管事件的影響[J]. 實用醫學雜志, 2025, 41(21): 3358-3364.
|
| 10. |
中華醫學會心血管病學分會心力衰竭學組, 中國醫師協會心力衰竭專業委員會中華心血管病雜志編輯委員會. 中國心力衰竭診斷和治療指南2018[J]. 中華心血管病雜志, 2018, 46(10): 760-789.
|
| 11. |
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018)[J]. J Am Coll Cardiol, 2018, 72(18): 2231-2264.
|
| 12. |
Macdonald MI, Shafuddin E, King PT, et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease[J]. Lancet Respir Med, 2016, 4(2): 138-148.
|
| 13. |
張叢溪, 陳亞紅. 肺功能檢查在慢性阻塞性肺疾病合并心血管疾病中的應用[J]. 中國醫學前沿雜志(電子版), 2024, 16(6): 13-17.
|
| 14. |
中華醫學會, 中華醫學會雜志社, 中華醫學會全科醫學分會, 等. 中國慢性阻塞性肺疾病基層診療與管理指南(2024年)[J]. 中華全科醫師雜志, 2024, 23(6): 578-602.
|
| 15. |
中華預防醫學會, 中華預防醫學會心臟病預防與控制專業委員會, 中華醫學會糖尿病學分會, 等. 中國健康生活方式預防心血管代謝疾病指南[J]. 中華健康管理學雜志, 2020, 14(2): 113-134.
|
| 16. |
王昕, 呂筠, 郭彧, 等. 中國慢性病前瞻性研究: 10個項目地區成年人群吸煙行為特征差異分析[J]. 中華流行病學雜志, 2015, 36(11): 1200-1204.
|
| 17. |
Kotlyarov S. The role of smoking in the mechanisms of development of chronic obstructive pulmonary disease and atherosclerosis[J]. Int J Mol Sci, 2023, 24(10): 8725.
|
| 18. |
Ragnoli B, Chiazza F, Tarsi G, et al. Biological pathways and mechanisms linking COPD and cardiovascular disease[J]. Ther Adv Chronic Dis, 2025, 16: 20406223251314286.
|
| 19. |
Den Ruijter HM, Haitjema S, Asselbergs FW, et al. Sex matters to the heart: a special issue dedicated to the impact of sex related differences of cardiovascular diseases[J]. Atherosclerosis, 2015, 241(1): 205-207.
|
| 20. |
Betai D, Ahmed A S, Saxena P, et al. Gender disparities in cardiovascular disease and their management: a review[J]. Cureus, 2024, 16(5): e59663.
|
| 21. |
惠靜瑤, 李龍. 雌激素參與慢性阻塞性肺疾病發病機制的研究進展[J]. 中國呼吸與危重監護雜志, 2026, 25(4): 284-288.
|
| 22. |
Tseng CH, Jou BY, Shen HC, et al. Increased risk of acute exacerbation in obstructive airway disease: the impact of metabolic dysfunction-associated steatotic liver disease and small airway dysfunction[J]. BMJ Open Respir Res, 2025, 12: e003352.
|
| 23. |
Okada A, Sugano Y, Nagai T, et al. Prognostic value of prothrombin time international normalized ratio in acute decompensated heart failure-a combined marker of hepatic insufficiency and hemostatic abnormality[J]. Circ J, 2016, 80(4): 913-923.
|
| 24. |
Fukuhara A, Saito J, Sato S, et al. The association between risk of airflow limitation and serum uric acid measured at medical health check-ups[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 1213-1219.
|
| 25. |
Aggarwal T, Wadhwa R, Rohil V, et al. Biomarkers of oxidative stress and protein-protein interaction in chronic obstructive pulmonary disease[J]. Arch Physiol Biochem, 2018, 124(3): 226-231.
|
| 26. |
中國老年醫學學會呼吸病學分會慢性阻塞性肺疾病學組. 中國老年慢性阻塞性肺疾病臨床診治實踐指南[J]. 中華結核和呼吸雜志, 2020, 43(2): 100-119.
|
| 27. |
Yu W, Cheng JD. Uric acid and cardiovascular disease: an update from molecular mechanism to clinical perspective[J]. Front Pharmacol, 2020, 11: 582680.
|
| 28. |
Kuo HK, Al Snih S, Kuo YF, et al. Chronic inflammation, albuminuria, and functional disability in older adults with cardiovascular disease: the National Health and Nutrition Examination Survey, 1999-2008[J]. Atherosclerosis, 2012, 222(2): 502-508.
|
| 29. |
楊文武, 馬娟. 血常規衍生免疫炎癥標志物與冠狀動脈疾病的相關性研究進展[J]. 現代醫藥衛生, 2025, 41(8): 1959-1963,1967.
|
| 30. |
Hamada K, Oishi K, Yamamoto T, et al. Impact of frailty on major adverse cardiovascular events in chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2025, 20: 3111-3122.
|
| 31. |
殷夢, 李子進. B型鈉尿肽和N末端B型鈉尿肽前體對老年慢性阻塞性肺疾病合并心力衰竭的診斷價值[J]. 中華老年心腦血管病雜志, 2024, 26(9): 1020-1025.
|
| 32. |
張蕾. 慢性阻塞性肺疾病伴下呼吸道感染患者血清NT-proBNP及PCT水平變化[J]. 中國防癆雜志, 2025, 47(S1): 181-183.
|
| 33. |
羅威, 張原琪. NT-proBNP在心血管系統疾病中的應用進展[J]. 國際醫藥衛生導報, 2022, 28(7): 942-946.
|
| 34. |
Liu H, Chen AG. Integrating lung function parameters into the framingham score for improved CVD risk prediction in COPD: a cross-sectional study based on NHANES 2007-2012[J]. COPD, 2026, 23(1): 2628586.
|
| 35. |
Uysal OF, Joseph T, Alharbi AM, et al. Methods to assess atherosclerotic cardiovascular risk in chronic respiratory diseases: a systematic review[J]. Euro Respir Rev, 2025, 34(178): 250050.
|
| 36. |
Qu S, Zhu J. A nomogram for predicting cardiovascular diseases in chronic obstructive pulmonary disease patients[J]. J Healthc Eng, 2022, 2022: 6394290.
|
| 37. |
商麗, 顧臨月, 李偉, 等. 老年慢性阻塞性肺疾病患者主要不良心血管事件的發生風險[J]. 中華老年心腦血管病雜志, 2025, 27(9): 1273-1275.
|
| 38. |
Xu Z, Li F, Xin Y, et al. Prognostic risk prediction model for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD): a systematic review and meta-analysis[J]. Respir Res, 2024, 25(1): 410.
|